Literature DB >> 32330245

EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.

Ayaka Yamaoka1, Mikiko Suzuki2, Saori Katayama1,3,4, Daiki Orihara1, James Douglas Engel5, Masayuki Yamamoto1,4,5.   

Abstract

Chromosomal rearrangements between 3q21 and 3q26 elicit high-risk acute myeloid leukemia (AML), which is often associated with elevated platelet and megakaryocyte (Mk) numbers. The 3q rearrangements reposition a GATA2 enhancer near the EVI1 (or MECOM) locus, which results in both EVI1 overexpression and GATA2 haploinsufficiency. However, the mechanisms explaining how the misexpression of these 2 genes individually contribute to leukemogenesis are unknown. To clarify the characteristics of differentiation defects caused by EVI1 and GATA2 misexpression and to identify the cellular origin of leukemic cells, we generated a system to monitor both inv(3) allele-driven EVI1 and Gata2 expression in 3q-rearranged AML model mice. A cell population in which both EVI1 and Gata2 were highly induced appeared in the bone marrows before the onset of frank leukemia. This population had acquired serial colony-forming potential. Because hematopoietic stem/progenitor cells (HSPCs) and Mks were enriched in this peculiar population, we analyzed the independent EVI1 and GATA2 contributions to HSPC and Mk. We found that inv(3)-driven EVI1 promotes accumulation of Mk-biased and myeloid-biased progenitors, Mks, and platelets, and that Gata2 heterozygous deletion enhanced Mk-lineage skewing of EVI1-expressing progenitors. Notably, inv(3)-directed EVI1 expression and Gata2 haploinsufficient expression cooperatively provoke a leukemia characterized by abundant Mks and platelets. These hematological features of the mouse model phenocopy those observed in human 3q AML. On the basis of these results, we conclude that inv(3)-driven EVI1 expression in HSPCs and Mks collaborates with Gata2 haploinsufficiency to provoke Mk-lineage skewing and leukemogenesis with excessive platelets, thus mimicking an important feature of human AML.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32330245      PMCID: PMC7189294          DOI: 10.1182/bloodadvances.2019000978

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  29 in total

1.  The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML.

Authors:  C Haferlach; U Bacher; T Haferlach; F Dicker; T Alpermann; W Kern; S Schnittger
Journal:  Leukemia       Date:  2011-02-01       Impact factor: 11.528

2.  Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study.

Authors:  L M Secker-Walker; A Mehta; B Bain
Journal:  Br J Haematol       Date:  1995-10       Impact factor: 6.998

3.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

Authors:  M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

4.  Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells.

Authors:  Meng Zhao; John M Perry; Heather Marshall; Aparna Venkatraman; Pengxu Qian; Xi C He; Jasimuddin Ahamed; Linheng Li
Journal:  Nat Med       Date:  2014-10-19       Impact factor: 53.440

5.  EVI1 induces myelodysplastic syndrome in mice.

Authors:  Silvia Buonamici; Donglan Li; Yiqing Chi; Rui Zhao; Xuerong Wang; Larry Brace; Hongyu Ni; Yogen Saunthararajah; Giuseppina Nucifora
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

6.  Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3.

Authors:  A P Grigg; R D Gascoyne; G L Phillips; D E Horsman
Journal:  Br J Haematol       Date:  1993-01       Impact factor: 6.998

7.  Defining the functional boundaries of the Gata2 locus by rescue with a linked bacterial artificial chromosome transgene.

Authors:  William Brandt; Melin Khandekar; Norio Suzuki; Masayuki Yamamoto; Kim-Chew Lim; James Douglas Engel
Journal:  J Biol Chem       Date:  2008-01-21       Impact factor: 5.157

8.  A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.

Authors:  Hiromi Yamazaki; Mikiko Suzuki; Akihito Otsuki; Ritsuko Shimizu; Emery H Bresnick; James Douglas Engel; Masayuki Yamamoto
Journal:  Cancer Cell       Date:  2014-04-03       Impact factor: 31.743

9.  Functionally Distinct Subsets of Lineage-Biased Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions.

Authors:  Eric M Pietras; Damien Reynaud; Yoon-A Kang; Daniel Carlin; Fernando J Calero-Nieto; Andrew D Leavitt; Joshua M Stuart; Berthold Göttgens; Emmanuelle Passegué
Journal:  Cell Stem Cell       Date:  2015-06-18       Impact factor: 24.633

10.  CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells.

Authors:  H Nakano; M Yanagita; M D Gunn
Journal:  J Exp Med       Date:  2001-10-15       Impact factor: 14.307

View more
  6 in total

Review 1.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

Review 2.  EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.

Authors:  Christine Birdwell; Warren Fiskus; Tapan M Kadia; Courtney D DiNardo; Christopher P Mill; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2021-03-22       Impact factor: 11.037

3.  Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.

Authors:  Sandra Kiehlmeier; Mahmoud-Reza Rafiee; Ali Bakr; Jagoda Mika; Sabrina Kruse; Judith Müller; Sabrina Schweiggert; Carl Herrmann; Gianluca Sigismondo; Peter Schmezer; Jeroen Krijgsveld; Stefan Gröschel
Journal:  Leukemia       Date:  2021-04-28       Impact factor: 12.883

4.  European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.

Authors:  Alex Bataller; Ana Garrido; Francesca Guijarro; Guadalupe Oñate; Marina Diaz-Beyá; Montserrat Arnan; Mar Tormo; Susana Vives; María Paz Queipo de Llano; Rosa Coll; David Gallardo; Ferran Vall-Llovera; Lourdes Escoda; Antonio Garcia-Guiñon; Olga Salamero; Antònia Sampol; Brayan M Merchan; Joan Bargay; Sandra Castaño-Díez; Daniel Esteban; Aina Oliver-Caldés; Andrea Rivero; Pablo Mozas; Mònica López-Guerra; Marta Pratcorona; Lurdes Zamora; Dolors Costa; Maria Rozman; Josep F Nomdedéu; Dolors Colomer; Salut Brunet; Jorge Sierra; Jordi Esteve
Journal:  Blood Adv       Date:  2022-02-22

Review 5.  Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?

Authors:  Emery H Bresnick; Mabel M Jung; Koichi R Katsumura
Journal:  Blood Adv       Date:  2020-09-22

6.  GATA2 deficiency syndrome: A decade of discovery.

Authors:  Claire C Homan; Parvathy Venugopal; Peer Arts; Nur H Shahrin; Simone Feurstein; Lesley Rawlings; David M Lawrence; James Andrews; Sarah L King-Smith; Natasha L Harvey; Anna L Brown; Hamish S Scott; Christopher N Hahn
Journal:  Hum Mutat       Date:  2021-08-31       Impact factor: 4.700

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.